Declining measles antibodies in the era of elimination: Australia's experience

被引:39
作者
Gidding, Heather F. [1 ,2 ]
Quinn, Helen E. [2 ]
Hueston, Linda [3 ]
Dwyer, Dominic E. [3 ]
McIntyre, Peter B. [2 ]
机构
[1] Univ New South Wales, UNSW Med, Sch Publ Hlth & Community Med, Sydney, NSW, Australia
[2] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia
[3] Westmead Hosp, Ctr Infect Dis & Microbiol Lab Serv, New South Wales Hlth Pathol, Inst Clin Pathol & Med Res, Westmead, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Measles; Seroprevalence; Vaccination; Immunity; RUBELLA ANTIBODIES; CONTROL CAMPAIGN; MMR VACCINE; B-CELL; IMMUNITY; MUMPS; CHILDREN; SEROPREVALENCE; PERSISTENCE; POPULATION;
D O I
10.1016/j.vaccine.2017.12.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Australia is one of only a few countries with a long-standing and consistent serosurveillance program. We conducted a national serosurvey in 2012-2013 to estimate population seroprevalence of measles-specific IgG and the effective reproduction number, R, and compare the results with the three previous serosurveys (1996-1999, 2002 and 2007) to examine trends following a decade of sustained measles control. Methods: 2729 residual sera from 1 to 49 year olds were tested using the Enzygnost anti-measles IgG enzyme immunoassay (EIA). All sera in the equivocal range by EIA on re-testing and a random sample of low positive and negative sera were later tested by a microneutralisation assay. R was calculated from weighted estimates of the proportion seronegative by age using a previously developed contact matrix. Results: In the 2012-13 serosurvey, anti-measles IgG seropositivity for 1-49 year olds was 80.8% (95% CI: 79.4-82.3%) and 8.9% (95% CI: 7.8-10.0%) had equivocal antibody levels. The increasing proportion of seronegative and equivocal individuals in age groups 10-39 years continued a trend seen in previous serosurveys. There was also an increase in equivocal results among 2-4 and 5-9 year old children, >90% of whom were recently vaccinated. R increased from 0.57 in 1999 to above the epidemic threshold of 1 in 2012-13 (R = 1.7). All 20 EIA negative sera, 238/241 (98.8%) equivocal sera, and 89/92 (96.7%) low positive sera had a titre <10 (negative) in the measles microneutralisation assay. Conclusions: A number of countries with sustained measles control have now demonstrated that measles-specific IgG antibodies decline with time since vaccination. As there is good epidemiologic evidence of population-level protection, the implications of declining measles-specific IgG antibody levels for maintaining measles elimination are unclear. Novel studies to determine correlates of protection against measles transmission and disease in the post-elimination era are needed to help answer this question. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:507 / 513
页数:7
相关论文
共 38 条
[1]   Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010 [J].
Ang, L. W. ;
Lai, F. Y. ;
Tey, S. H. ;
Cutter, J. ;
James, L. ;
Goh, K. T. .
EPIDEMIOLOGY AND INFECTION, 2013, 141 (08) :1721-1730
[2]  
[Anonymous], 3 ANN M REG VER COMM
[3]  
[Anonymous], AUSTR IMM HDB
[4]   Neutralizing B cell response in measles [J].
Bouche, FB ;
Ertl, OT ;
Muller, CP .
VIRAL IMMUNOLOGY, 2002, 15 (03) :451-471
[5]   Waning population immunity to measles in Taiwan [J].
Chen, Chih-Jung ;
Lee, Ping-Ing ;
Hsieh, Yu-Chia ;
Chen, Po-Yen ;
Ho, Yu-Huai ;
Chang, Chee-Jen ;
Liu, Ding-Ping ;
Chang, Feng-Yee ;
Chiu, Cheng-Hsun ;
Huang, Yhu-Chering ;
Lee, Chin-Yun ;
Lin, Tzou-Yien .
VACCINE, 2012, 30 (47) :6721-6727
[6]   Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: A 20-year follow-up [J].
Davidkin, Irja ;
Jokinen, Sari ;
Broman, Mia ;
Leinikki, Pauli ;
Peltola, Heikki .
JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (07) :950-956
[7]  
De Serres G, 2000, AM J EPIDEMIOL, V151, P1039, DOI 10.1093/oxfordjournals.aje.a010145
[8]  
DIEKMANN O, 1990, J MATH BIOL, V28, P365
[9]   Modelling the incidence of measles in Canada: an assessment of the options for vaccination policy [J].
Gay, NJ ;
Pelletier, L ;
Duclos, P .
VACCINE, 1998, 16 (08) :794-801
[10]   Verification of measles elimination in Australia: Application of World Health Organization regional guidelines [J].
Gidding H.F. ;
Martin N.V. ;
Stambos V. ;
Tran T. ;
Dey A. ;
Dowse G.K. ;
Kelly H.A. ;
Durrheim D.N. ;
Lambert S.B. .
Journal of Epidemiology and Global Health, 2016, 6 (3) :197-209